relationships. It is to be hoped that such a study will be conducted in association with one of the pilot screening programmes under way in a number of countries so that assessment of value and harm can be based on fact rather than on opinion.
While it may be a tragedy that some families discover that an older child has CF only after the birth of a second affected child, this must be seen in perspective. As stated in my commentary, only 7 % of patients are so diagnosed and 1 in 3 families who find they have 2 In all cases except 1, the infecting organism was Candida albicans, the exception being Torulopsis glabrata. At the time of infection all infants were receiving parenteral nutrition; 6 were preterm, gestational age 27-4±1-8 weeks (mean± SD), birthweight 1.01 ±020 kg, (mean ± SD), while the seventh was a term infant with necrotising enterocolitis. A combination of intravenous amphotericin B (0-25 mg/kg a day increasing to 1-0 mg/kg a day over 4 days) and flucytocine 100-150 mg/kg a day was given for 3 weeks followed by 2 weeks of oral flucytocine. Five infants were treated with combined therapy while 2 infants received flucytocine alone. Blood cultures were sterile after 48 hours except in I baby in which a C. albicans resistant to flucytocine was isolated before the addition of amphotericin B. In view of the reported side effects of these drugs all infants had twice weekly blood cultures, full blood count with differential white cell and platelet counts, urea and electrolytes, serum creatinine, and liver function tests. The only abnormalities were a marked increase in alkaline phosphatase and gamma glutamyltransferase in 5 infants. These changes were not appreciably different to those seen in 8 other preterm infants, gestational age 29-1±1-9 weeks (mean±SD), birthweight 0.93±0-37 kg (mean±SD) on parenteral nutrition without fungal septicaemia.
We would like to suggest that combined amphotericin B and flucytocine therapy is a treatment of choice in neonatal systemic fungal infection and that the above regimen has not led to the side effects reported by others.
Miconazole in systemic candidiasis
Sir, I wish to report another therapeutic failure of miconazole in a neonate with systemic candidiasis.1-3 The male infant weighed 1300 g at 29 weeks gestation and required assisted ventilation from day 3 for recurrent apnoea. Parenteral nutrition was given for 3 days through an umbilical arterial catheter and thereafter via silastic venous lines. At echocardiography for patent ductus arteriosus the tip of a silastic line was found to lie in the right ventricle. Candida albicans was cultured from its tip and also from blood and urine. Despite a 14 day course of miconazole (20 mg/kg a day from day 4, serum concentration I mg/i), C. albicans persisted in blood and urine cultures, apparently still sensitive to miconazole. Treatment was changed to amphotericin B (0-25 mg/kg a day-I mg/kg a day) and flucytosine (200 mg/kg a day) and after 8 days therapy all cultures were negative.
The infant died despite initial clinical improvement and the necropsy showed candida vegetations blocking the pulmonary artery. Careful catheter management and positioning4 is essential and the value of miconazole in treating systemic candidiasis in this age group must bquestioned. 
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